Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease Prognosis.
The PAX8/PPARγ fusion protein (PPFP) occurs in 36% of human follicular thyroid carcinoma (FTC) and is associated with favorable prognosis. To elucidate the function of PPFP in FTC, we analyzed the consequences of PPFP expression in immortalized thyrocytes in vitro and in vivo via xenograft tumorigenesis. While PPFP-expressing cells exhibited oncogenic hallmarks, including increased growth and decreased apoptosis, in vitro, xenograft tumors were initiated but not sustained in vivo. PPFP xenograft tumors exhibited reduced CD31 staining and VEGF expression, suggesting that PPFP modulates neovascularization. Microarray analysis demonstrated increased expression of tissue inhibitor of metalloproteinase (TIMP-3), an inhibitor of angiogenesis, in PPFP cells and tumors, a finding confirmed by quantitative PCR and immunohistochemistry. Immunohistochemical staining of archival human thyroid tumors demonstrates a significant decrease in CD31 staining in all adenomas and carcinomas containing the PAX8/PPARγ rearrangement. Decreased angiogenesis in PPFP-containing tumors is directly correlated with our observations in the xenograft model and provides evidence for the first time that PPFP may impact FTC tumorigenesis by modulating angiogenesis in vivo.
Reddi
H V
HV
Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Madde
P
P
Marlow
L A
LA
Copland
J A
JA
McIver
B
B
Grebe
S K G
SK
Eberhardt
N L
NL
Angiogenesis. 2005;8(4):373-9
16400517
Biochem Cell Biol. 1996;74(6):853-62
9164653
Clin Endocrinol (Oxf). 2007 Nov;67(5):706-11
17651453
J Immunol Methods. 1986 May 22;89(2):271-7
3486233
Oncogene. 2005 Nov 21;24(52):7729-45
16299533
Endocrinology. 2006 Jan;147(1):367-76
16179407
Cancer Res. 2008 Jun 15;68(12):4736-45
18559520
Eur J Endocrinol. 2004 Sep;151(3):367-74
15362967
Science. 2000 Aug 25;289(5483):1357-60
10958784
Invest Ophthalmol Vis Sci. 1997 Apr;38(5):817-23
9112976
Thyroid. 2007 Jun;17(6):497-509
17614769
Biochem J. 2006 Sep 15;398(3):515-9
16771712
J Clin Endocrinol Metab. 2003 Jan;88(1):354-7
12519876
Biochem Pharmacol. 2008 Dec 1;76(11):1544-53
18771658
Bull Cancer. 2005 Jan;92(1):37-43
15689324
Am J Pathol. 2003 Apr;162(4):1053-60
12651598
J Biol Chem. 2000 Oct 6;275(40):31226-32
10900194
Nat Genet. 2003 Aug;34(4):369-76
12923544
Mol Cell Endocrinol. 2010 May 28;321(1):50-6
19883731
Nat Med. 2003 Apr;9(4):407-15
12652295
Oncol Rep. 2008 Dec;20(6):1489-95
19020732
Oncogene. 2004 Apr 29;23(20):3634-41
15077183
Int J Cancer. 2003 Oct 10;106(6):848-55
12918061
J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52
12161538
J Surg Oncol. 2006 Dec 15;94(8):662-9
17131411
J Clin Endocrinol Metab. 2005 Jan;90(1):463-8
15483076
Nat Rev Cancer. 2002 Oct;2(10):795-803
12360282
Br J Cancer. 1989 Dec;60(6):897-903
2557880
Thyroid. 2005 May;15(5):422-6
15929662
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1983-93
16609007
J Exp Med. 1972 Aug 1;136(2):261-76
5043412
Mol Cell Endocrinol. 2010 May 28;321(1):36-43
19766698
Cancer Lett. 2005 Jun 1;223(1):137-42
15890246
Am J Pathol. 2005 Jul;167(1):223-31
15972966
Oncogene. 2005 Feb 17;24(8):1467-76
15608688
Leukemia. 2006 Jan;20(1):1-8
16281069
Semin Cancer Biol. 1992 Apr;3(2):65-71
1378311
J Immunol. 2005 May 15;174(10):6524-31
15879156
Endocrinology. 2009 Sep;150(9):4386-94
19541765
J Virol. 1989 Apr;63(4):1651-60
2538648
Cell. 2000 Jan 7;100(1):57-70
10647931
J Clin Endocrinol Metab. 2003 May;88(5):2318-26
12727991
PPAR Res. 2008;2008:309469
18596912
J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5
12970322
Int J Cancer. 2006 Nov 15;119(10):2322-9
16858683
Br J Cancer. 2004 Aug 16;91(4):732-8
15238980